V
TEVA icon

Veritable’s Teva Pharmaceuticals TEVA Stock Holding History

Veritable’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,580
Closed -$163K – 820
2018
Q4 		$163K Buy
+10,580
New +$217K ﹤0.01% 745
2016
Q3 		– Sell
-5,216
Closed -$262K – 746
2016
Q2 		$262K Buy
5,216
+26
+0.5% +$1.38K 0.01% 603
2016
Q1 		$278K Sell
5,190
-4,959
-49% -$291K 0.01% 590
2015
Q4 		$666K Buy
10,149
+4,939
+95% +$305K 0.02% 393
2015
Q3 		$294K Buy
5,210
+20
+0.4% +$1.3K 0.01% 582
2015
Q2 		$307K Sell
5,190
-10,396
-67% -$641K 0.01% 598
2015
Q1 		$971K Sell
15,586
-122
-0.8% -$7.09K 0.02% 414
2014
Q4 		$903K Sell
15,708
-376
-2% -$20.9K 0.02% 429
2014
Q3 		$865K Sell
16,084
-577
-3% -$30.6K 0.02% 444
2014
Q2 		$873K Buy
16,661
+2,552
+18% +$130K 0.02% 435
2014
Q1 		$746K Buy
14,109
+111
+0.8% +$5.13K 0.02% 469
2013
Q4 		$561K Sell
13,998
-6,689
-32% -$263K 0.01% 547
2013
Q3 		$782K Buy
20,687
+569
+3% +$22.2K 0.02% 446
2013
Q2 		$789K Buy
+20,118
New +$783K 0.02% 454

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Veritable's TEVA Position: Q1 2019 in Review

Veritable sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 10,580 shares — an estimated $163K sold.

Veritable first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $971K in Q1 2015. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Veritable reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Veritable sold 10,580 Teva Pharmaceuticals shares in Q1 2019, an estimated $163K.
  • Veritable first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Veritable's Teva Pharmaceuticals position peaked at $971K in Q1 2015.
  • 522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Veritable's 13F filing for Q1 2019, filed 15 May 2019.